Figure 2.

Promising new drugs or treatment strategies in NK/T cell lymphoma and their target. Pembrolizumab and nivolumab are both anti-PD1 antibodies, they were designed to target PD1 on the microenvironment T-cells, interrupting the connection of PD1 and PDL-1, and inhibiting activation. Daratumumab, a novel antibody targeting CD38 on the membrane of lymphoma cell, has shown particular efficacy in one case. LMP-specific CTLs are produced against lymphoma cells with membrane expression of LMP, and sequentially kill tumor cells. Signal pathways aberration and gene dysregulation are universally involved in lymphomagenesis, thus making molecule inhibitors an attractive target. JAK inhibitors, surviving, and EZH2 blocades have shown efficacy in some pre-clinical trials with favorable outcomes. The immunosuppressive agents, dexamethasone, and thalidomide, can efficaciously inhibit the TNF-α and IFN-γ released by lymphoma cells due to the ECSIT mutation, and relieve ENKL-associated hemophagocytic syndrome.